×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
TP53 was mutated in 13/63 (21%) cases, including 5/7 (71%) leukemic non-nodal and 8/56 (14%) conventional mantle cell lymphoma .
31296581
2020
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
30626249
2019
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
Biomarker
BEFREE
Our results: i) confirm that TP53 disruption identifies a high-risk population characterized by poor sensitivity to conventional or intensified chemotherapy; ii) provide the pivotal evidence that patients harboring KMT2D mutations share the same poor outcome as patients harboring TP53 disruption; and iii) allow to develop a tool for the identification of high-risk mantle cell lymphoma patients for whom novel therapeutic strategies need to be investigated.
31537689
2019
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
TP53 mutations are common in mantle cell lymphoma , including the indolent leukemic non-nodal variant.
31132650
2019
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
30537212
2019
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma .
30146365
2018
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
Biomarker
BEFREE
Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma .
28284458
2017
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
AlteredExpression
BEFREE
Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.
27074052
2016
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma .
26022239
2015
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
Biomarker
BEFREE
MDM4, the newly discovered modulator of p53 protein, is frequently amplified in various solid tumors such as cutaneous melanoma, retinoblastoma and hematological malignances such as chronic lymphocytic leukemia, acute myeloid leukemia and mantle cell lymphoma .
26567881
2015
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53 , ATM, and/or 13q14.
24852242
2014
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
Compared with patients without TP53 mutations, TP53 mutations were associated with risk factors including age, higher serum lactate dehydrogenase, lymphocytosis, high-risk (HR) international prognostic index, HR mantle cell lymphoma international prognostic index, complex karyotype, and higher occurrence of TP53 deletions.
22057359
2012
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
TP53 alterations are strongly associated with a high proliferation index and aggressive behavior in mantle cell lymphoma .
22315488
2012
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
Biomarker
BEFREE
Mantle cell lymphoma cell lines with known p53 status were treated with GUT-70, a tricyclic coumarin derived from Calophyllum brasiliense, and the biological and biochemical consequences of GUT-70 were studied.
21139584
2011
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
AlteredExpression
BEFREE
Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma .
20126990
2010
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53 -mutated mantle cell lymphoma .
20850924
2010
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
Biomarker
LHGDN
Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma .
18467333
2008
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
PosttranslationalModification
BEFREE
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma .
18765533
2008
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
AlteredExpression
BEFREE
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
16166592
2006
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
Cryptic and complex chromosomal rearrangements and the deletion of TP53 gene in a patient with leukemic mantle cell lymphoma .
16938577
2006
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
AlteredExpression
BEFREE
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma .
16461462
2006
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
Proliferative fraction, bcl-1 gene translocation, and p53 mutation status as markers in mantle cell lymphoma .
10085408
1999
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
We previously found that cases of typical B-chronic lymphocytic leukemia (CLL), atypical B-CLL with t(11;14) and mantle cell lymphomas characterized by rapid progression of the disease and resistance to therapy, had mutations of the TP53 gene.
9844609
1998
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
Biomarker
BEFREE
These findings indicate that in B-NHL, somatic changes in P53 were present in diagnostic specimens of all histologic types, but at a higher frequency in DLC and MC tumors.
9354678
1997
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.100
GeneticVariation
BEFREE
On the other hand, the molecular basis of some of these diseases (eg, the overexpression of the Prad1/CCND1 gene in mantle-cell lymphomas , the relationship between bcl-2 and bax expression in chronic lymphocytic leukemia homeostasis, the role of p53 tumor suppressor gene mutations in chronic lymphocytic leukemia progression) are increasingly well known.
9090492
1997